We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Liver disease company Promethera completes €17mm Series B round; raises €6.6mm in debt
01 May 2012
Executive Summary
Returning shareholder Vesalius Biocapital has led a €17mm ($23mm) Series B financing for Promethera Biosciences SA NV (hepatic progenitor cell therapeutics and predictive models of liver metabolism). Other Series A investors participating in the round included Société Régionale d'Investissement de Wallonie, Vives-Louvain Technology Fund, Life Science Research Partners, NivelInvest, Financière Spin-off Luxembourgeoise, Universite Catholique de Louvain's tech transfer arm Sopartec, and business angels. First-time backers Boehringer Ingelheim Venture Fund, Shire, Mitsui Global Investment, ATMI, and SambrInvest also joined. In addition, Promethera received €6.6mm in debt funding from the Walloon Region (one of Belgium’s three federal regions) to fund work on Promethera HepaStem, an alternative to liver transplant. The candidate--an injectable suspension of heterologous human adult liver progenitor cells--has been granted orphan drug status in the US and EU and was recently cleared by British and Belgian regulatory officials to begin a Phase I/II trial in children with Crigler-Najjar syndrome or urea cycle disorders.
Deal Industry
Pharmaceuticals
Biotechnology
Drug Discovery Tools
Gene Therapy, Cell Therapy
Deal Status
Final
Deal Type
Financing
Nonconvertible Debt
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?